Indivior Plc
INDV:LN
Latest Coverage
Overview
Company Profile
Indivior is a global pharmaceutical company working to help change patients’ lives by pioneering life-transforming treatment for addiction and other serious mental illnesses.
Indivior manufactures and markets medicines for the treatment of moderate to severe opioid use disorder with a global portfolio in over 40 countries.
Indivior also markets medicine for the treatment of schizophrenia in adults in the United States and has a licensing agreement to bring this treatment to patients suffering from schizophrenia in Canada.
Classification
Sector Healthcare
Industry Pharmaceuticals
Subindustry Pharmaceutical Manufacturers - Specialty & Generic
Financials
News & Media
Corporate
Board of Directors
Howard Pien
Chairman
Howard has worked in the pharmaceutical and biotechnology industries for over 30 years. Howard is currently a Board Director of the development-stage biopharmaceuticals companies: Bellerophon, Immunogen, Juno and Sage; and Vanda, a commercial-stage public company specializing in CNS (four years as Chairman); as well as the Chairman designee of Reckitt Benckiser Pharmaceutical. He is an advisor to the Life Sciences Practice of Warburg Pincus, a private equity firm. Howard’s non-profit board appointments include the industry associations BIO and PhRMA, as well as Oakland Children’s Hospital and Fox Chase Hospital. From 2007 to 2009, Howard was the Chairman and CEO of Medarex, Inc., a public biotechnology company, until it was acquired by Bristol-Myers Squibb. From 2003 to 2006, he was the Chairman and CEO of Chiron, a public biotechnology company, which was acquired by Novartis. His previous Board directorships include Talon, Arresto, Ikaria and Biopharma (where he was lead independent director) – all biopharmaceutical companies that were acquired in strategic transactions. Between 1991 and 2003, he held various executive positions at GlaxoSmithKline plc (GSK) and SmithKline Beecham, as Presidents of US, International, and Pharmaceuticals. Prior to GSK, Howard worked for Abbott Labs for six years and Merck & Co., Inc. for five years. Howard graduated from MIT with a BS in engineering, and from Carnegie-Mellon University with an MBA.
Shaun Thaxter
Chief Executive Officer
Shaun was appointed CEO of Indivior in 2014. Since 2009, Shaun led the Reckitt Benckiser Pharmaceuticals (RBP) business as CEO with a remit to build a global company through the acquisition of the global marketing rights from Merck, and he ensured its successful integration to accelerate RBP towards its vision. He has spearheaded the successful growth and development of RBP since launching the US Suboxone business in 2003. Following his formal appointment as President of RBP in 2005, Shaun led RBP through sustained growth, building a lifecycle management pipeline and expanded addiction franchise that grew from zero to a peak of $1.5 billion in net revenue. Today, under his leadership, Indivior successfully operates in 46 countries around the world. Shaun joined Reckitt & Colman in 1995 as Senior Brand Manager and advanced to Category Manager within the Company’s UK Healthcare business. Following the 1999 merger with Benckiser, he was appointed Global Category Manager for the prescription product portfolio. Shaun graduated from Kings College, London with a Joint Honors B.S. in biochemistry and physiology and undertook his early career with Proctor & Gamble and London International Group.
Cary J. Claiborne
Chief Financial Officer
Cary was appointed CFO of Indivior in November 2014. Prior to joining Indivior, Cary had been the CFO of Sucampo Pharmaceuticals, Inc. a public global biopharmaceutical company focused on discovery, development, and commercialization, from 2011 to 2014. From 2009 to 2010, Cary was President, CEO, and a member of the board of directors of New Generation Biofuels, Inc., a public biofuel technology company, as well as its CFO from 2007 to 2009. Previously, Cary had been CFO of Osiris Therapeutics, Inc., a public stem cell therapeutics company, leading the company’s initial public offering in 2006. From 2001 to 2004, he was Vice President –FP&A of Constellation Energy Group, a diversified energy company. Prior to that position, he had been Vice President –FP&A of The Home Depot, Inc. and an employee of MCI Corporation. Cary spent the first 15 years of his career in a series of progressively more responsible positions in financial management and senior management, including President and CEO of New Enterprise Wholesale Services at GE Capital and GE since 1982. Cary is also a member of the board of directors of MedicAlert Foundation, where he also serves as the Chairman of their Finance Committee. Cary graduated from Rutgers University with a B.A. in Business Administration and from Villanova University with an M.B.A.
Rupert Bondy
Senior Independent Director
Rupert joined energy company BP in 2008 as Group General Counsel, with worldwide responsibility for legal and compliance matters. He is a member of the English Bar and the California Bar as well as various professional bodies and committees. Rupert began his career as a lawyer in private practice. In 1989, he joined US law firm Morrison & Foerster, working in San Francisco and London, and from 1994 he worked for UK law firm Lovells in London. In 1995, he joined SmithKline Beecham as Senior Counsel for mergers and acquisitions and other corporate matters. He subsequently held positions of increasing responsibility and, following the merger of SmithKline Beecham and Glaxo Wellcome to form GlaxoSmithKline, in 2001 he was appointed Senior Vice President and General Counsel. Rupert obtained his undergraduate degree from Kings College, Cambridge and was then a Harkness fellow for a year at Harvard University. He also spent a year as a teaching fellow at Stanford Law School, where he obtained a masters degree in law. Chairman of the Governance and Nomination Committee. Member of Remuneration Committee.
Yvonne Greenstreet
Independent Non-Executive Director
Yvonne has more than 20 years of global experience in the pharmaceutical industry, spanning research and development, strategy and commercial development. Yvonne serves on the boards of directors of Pacira Pharmaceuticals and Advanced Accelerator Applications. She is also on the advisory board of the Bill and Melinda Gates Foundation. Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer and a member of the global executive team for the $16 billion Specialty Business with accountability for a portfolio that included the immuno-inflammation, vaccine, specialty neuroscience, and rare disease areas. Prior to Pfizer, she was at Glaxo SmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development, serving on the corporate executive investment committee. She was responsible for enabling strategy development and execution to achieve GSK’s goal of delivering five to seven new medicines per year while reducing research and development spend. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicine Development and Chief Medical Officer for Europe. Yvonne trained as a physician and earned her medical degree from Leeds University in the UK and her M.B.A. from INSEAD, France. She was recognized by Fast Company as one of the 100 most creative people in business in the US in 2013 and by Fierce Biotech as one of the top ten women in biotechnology in 2012. Chairman of the Science and Policy Committee. Member of the Audit Committee.
Adrian Hennah
Non-Executive Director
Adrian is Chief Finance Officer of Reckitt Benckiser Group plc, which he joined in January 2013. He is also a Non-Executive Director of Reed Elsevier plc and Reed Elsevier NV. Adrian was Chief Financial Officer of Smith & Nephew plc from June 2006 to December 2012. Prior to Smith & Nephew, Adrian was Chief Financial Officer of Invensys plc for four years and spent 18 years at GlaxoSmithKline plc, where he held a number of senior management and financial roles. Earlier in his career, Adrian worked at PwC (then Price Waterhouse) in both auditing and consultancy. Adrian has a degree in law from Cambridge University and is a Sloan Fellow of the London Business School. Member of the Audit Committee.
A. Thomas McLellan
Independent Non-Executive Director
Tom has been a career researcher for 35 years with the Treatment Research Institute (which he co-founded in 1992) and the University of Pennsylvania. During his career, Tom has published over 400 articles and chapters on addiction research. He has received several awards including Life Achievement Awards from the American, Swedish, Italian and British Societies of Addiction Medicine and from the American Public Health Association in 2010. During 2009 through 2011, Tom was unanimously confirmed by the US Senate to serve as Deputy Director of the White House Office of National Drug Control Policy, where he was one of the principal authors of the President’s National Drug Control Strategy. Tom holds a B.A. from Colgate University and an M.S. and Ph.D. from Bryn Mawr College. He received postgraduate training in psychology at Oxford University in England. Member of the Governance and Nomination Committee. Member of the Science and Policy Committee.
Lorna Parker
Independent Non-Executive Director
Lorna is a senior adviser at BC Partners, a leading private equity firm. As an independent consultant, she conducts board effectiveness reviews for UK public companies. She has an active not-for-profit portfolio: a Trustee of the Royal Horticultural Society, a Director of Future Academies, a Governor of Pimlico Academy, a Trustee of BC Partners Foundation and until recently, a Trustee of Place2Be. Lorna’s executive career was primarily in executive recruitment, as a partner at Spencer Stuart. Lorna created and led their private equity practice across Europe, co-led the legal search practice globally, was a member of the UK board practice and was managing director of the UK business. Prior to joining Spencer Stuart, Lorna worked for venture capital firm Advent and investment bank Kleinwort Benson. Lorna has an MA Economics from Cambridge University and MBA from Stanford Business School, where she was a Harkness Fellow. Member of the Governance and Nomination Committee. Member of the Remuneration Committee.
Daniel J. Phelan
Independent Non-Executive Director
Dan is a Board Director of TE Connectivity (formerly Tyco Electronics) and serves on the Management Development & Compensation Committee. He is a member of the Health Care and Life Sciences Advisory Board of Computer Sciences Corporation and the Advisory Board of RiseSmart. He is also an Executive Director of Executive Networks and is a member of the Board of Trustees of Rutgers University. Dan retired from GlaxoSmithKline plc in December 2012 after 31 years, during which he was an advisor to three chief executives and was a member of the Corporate Executive Team. Prior to his retirement, he was Chief of Staff with global responsibility for Corporate Strategy and Development, Human Resources, Information Technology, Real Estate and Facilities, Environmental Health and Safety, and Security. Before that, he was Senior Vice-President, Human Resources for fourteen years. Dan is a graduate of Rutgers College. He holds a Master’s degree from The Ohio State University and a law degree from Rutgers University School of Law. He is admitted to practice in New Jersey and Pennsylvania. Dan served as an officer on active duty and the reserves in the U.S. Army Medical Service Corps. He has published on CEO succession planning and onboarding and public sector collective bargaining. Chairman of the Remuneration Committee. Member of the Governance and Nomination Committee.
Christian Schade
Independent Non-Executive Director
Chris is Chief Executive Officer of Novira Therapeutics Inc., a privately held biopharmaceutical company. He is a Board Director of Integra Life Sciences and a member of its Audit Committee and Chair of its Finance Committee. Chris also chairs the Board of Trustees at Princeton Academy School. Chris was previously Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc., a specialty pharmaceutical company, prior to its disposal in July 2013 to AstraZeneca for potentially up to $445 million. He was EVP and CFO at NRG Energy from March 2010 to September 2011. Chris joined Medarex Inc., in 2000 and helped it grow to become a leading pharmaceutical development company and, as Senior Vice President Administration and Chief Financial Officer, played a lead role in the negotiations for Bristol-Myers Squibb Co.’s $2.4 billion acquisition of Medarex in September 2009 and the subsequent merger-integration process. Prior to Medarex, Chris served as Managing Director and head of the European Corporate Funding Group at Merrill Lynch in London and also held various capital markets and corporate finance positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Christian received an A.B. from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania. Chairman of the Audit Committee. Member of the Science and Policy Committee
Daniel Tassé
Independent Non-Executive Director
Daniel was Chairman and CEO of Ikaria, Inc. until its acquisition by Mallinckrodt Pharmaceuticals in April 2015. He had served as Ikaria’s President and CEO since 2008, and was appointed Chairman of the Board of Directors in October 2009. Daniel oversaw the spinout of Bellerophon Therapeutics from Ikaria in 2013, creating two companies to best leverage the scientific, financial, and marketing strengths of the company. Daniel is a director of Bellerophon Therapeutics. Daniel is a member of the Healthcare Leadership Council. Until the sale of Ikaria, Daniel was a member of the Board of Directors and Health Section Governing Board of the Biotechnology Industry Organization (BIO), where he participated on the bioethics, regulatory environment, and reimbursement committees, and a Board Director of PhRMA, where he participates on the FDA and Biomedical Research Committee. Prior to joining Ikaria, Daniel served as General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International. Earlier in his career, he held a number of senior management positions at GlaxoSmithKline (GSK); from 2001 to 2004, he was Vice President and Regional Director for Australasia at GSK. Daniel holds a B.S. in Biochemistry from the University of Montreal. Member of the Audit Committee. Member of the Remuneration Committee.
Kathryn Hudson
Company Secretary
Kathryn is a Chartered Secretary who has over fifteen years of experience working for UK listed companies. Prior to joining Indivior, Kathryn was Company Secretary of Kingfisher plc, one of Europe’s largest retailers and Deputy Company Secretary of Burberry Group plc.